cell-mediated reaction to either a specific virus or several viruses, some of them hepatotropic” is unwarranted on the evidence provided. In the authors’ own words, these data are “too vague or speculative” to provide any real insight into the enigma of the relationship of lichen planus and hepatic disease.

F. E. C. Powell, M.D.
Regional Center of Dermatology
Mater Hospital
Dublin, Ireland
ROY S. ROGERS III, M.D.
Department of Dermatology
E. ROLLAND DICKSON, M.D.
Division of Gastroenterology
Mayo Clinic
Rochester, Minnesota 55905

REFERENCES

HOW DOES ENDOSCOPIC SCLEROTHERAPY ALTER SPLANCHNIC HEMODYNAMICS?


ABSTRACT

Endoscopic sclerotherapy is widely employed for esophageal variceal hemorrhage. However it has side effects and can aggravate portal hypertension by suppression of portosystemic shunt. The purpose of the present investigation was to study the effect of variceal thrombosis on hepatic venous pressure gradient and azygos blood flow. Eight alcoholic cirrhotic patients with a first variceal hemorrhage were included. According to Child Pugh’s classification, 4 patients were group A, 2 group B and 2 group C. At each session 40 to 60 ml of 1 p. 100 polidocanol were injected into the varices. A hemodynamic study was performed in each patient before and about 1 week after variceal obliteration (mean 3.3 procedures). Mean value of hepatic venous pressure gradient was 16.6 ± 5.5 mm Hg and 17.0 ± 3.8, respectively, before sclerotherapy and after eradication of varices; azygos blood flow 663 ± 506 ml/min before and 682 ± 522 after; cardiac output was 6.5 ± 0.7 ml/min before and 6.5 ± 0.8 after. None of these differences were significant. These results suggest that endoscopic sclerotherapy using polidocanol does not change hepatic venous pressure gradient and azygos blood flow, and does not lower blood flow through the gastroesophageal collaterals draining into the azygos vein. This is consistent with the hypothesis that thrombosis remains localized.

COMMENTS

In his first report of endoscopic sclerotherapy (EST) of esophageal varices (EV) in 1947, Moersch suggested that EST may increase the risk of bleeding from gastric varices, and he considered that the presence of gastric fundal varices was a contraindication to the use of EST. Since then, the potential hazard of EST in aggravating the consequences of portal hypertension has been debated. The hypothesis is that EST, by occluding EV and, perhaps, para-EV, could thereby reduce the collateral vessels that shunt blood from the gastric veins. Another hazard of EST that has been suggested is the occurrence of thrombosis in a major vessel of the portal venous system, which could increase the portal venous pressure.

Bourbon et al. suggested, in the work under discussion, that EST using polidocanol did not significantly alter the hepatic venous pressure gradient and azygos blood flow in eight patients with alcoholic cirrhosis who had recently bled from ruptured EV. This interesting study deserves several comments. First, no control group existed. As stated by the authors, this was not thought possible for ethical reasons. However, it greatly limits the conclusions achievable because it has been suggested that a progressive decrease in portal pressure occurs after a bleeding event (1) and that portal venous pressure falls spontaneously in alcoholic cirrhotic patients who have not bled from varices, especially in those patients who abstained from alcohol (2). Second, the number of patients is low, and large intraindividual variations were observed (e.g., portal venous pressure fell by 59% in one patient. Third, the use of the thermal dilution method for prolonged periods to detect chronic variations in azygos blood flow has not been established. This measurement is technically difficult, and the displacement of the catheter between serial measurements may introduce methodological errors because it is not clear that blood flow is measured in precisely the same way. Finally, the authors’ results cannot be extrapolated to those with other sclerosing agents because it has been suggested that EST with ethanolamine decreases azygos blood flow by almost one fourth after eradication of EV (3). It has also been suggested that ethanolamine is superior to polidocanol for the eradication of EV and the prevention of rebleeding (4), even though it has also been suggested that the recurrence of EV in patients receiving EST with ethanolamine is caused by incomplete obliteration of the venous feeders of the varices (5).

In three other studies, EST did not significantly alter portal venous pressure (6). On the other hand, several reports have noted gastric or ectopic variceal bleeding after EST (6), and it has been suggested that EST significantly increases the prevalence of large spleno-
renal shunts (7). Moreover, D'Amico et al. (8) have suggested that EST is an independent risk factor for the development of portal hypertensive gastropathy. Finally, the role of EST in inducing portal vein thrombosis is debated (9, 10).

In conclusion, some discrepancies exist between hemodynamic and clinical studies on the venous consequences of EST. EST appears to enhance the development of large shunts or congestive gastropathy and to occlude para-EV in some patients. On the other hand, EST does not have a significant effect on splanchnic hemodynamics. These discrepancies could be explained by differences in the nature of the sclerosing agents used and by the limitations of the hemodynamic findings in relation to the time of bleeding.

PAUL CALÈS, M.D.
Liver Unit,
Centre Hospitalier Universitaire
49033 Angers, France

REFERENCES